LIQUIDIA CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
LIQUIDIA CORPORATION (LQDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.34% for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2022-05-12
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.34%, a 40.12% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 1.67%, a 4.37% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.60%.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.67%, a 4.37% increase from fiscal 2020.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 1.60%, a 33.33% decline from fiscal 2019.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2019 was 2.40%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2022-03-31 | 2.34% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 1.67% 10-K · filed 2022-03-17 | |||
| 2021-09-30 | 1.67% 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | 1.67% 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | 1.67% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 1.60% 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 1.60% 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | 1.60% 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | 1.60% 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 2.40% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |